

# Michael A Morse

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5136366/publications.pdf>

Version: 2024-02-01

211  
papers

11,222  
citations

61984

43  
h-index

31849

101  
g-index

218  
all docs

218  
docs citations

218  
times ranked

14730  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 217-226.  | 4.1 | 2         |
| 2  | Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. , 2022, 10, e003717.   |     | 27        |
| 3  | Abstract P1-04-07: Xiap expression is associated with infiltration of cd163+ tumor-associated macrophages in the tumor micro-environment of inflammatory breast cancer. <i>Cancer Research</i> , 2022, 82, P1-04-07-P1-04-07.   | 0.9 | 1         |
| 4  | Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3510-3510.                              | 1.6 | 13        |
| 5  | Vaccine Therapies for Cancer: Then and Now. <i>Targeted Oncology</i> , 2021, 16, 121-152.   | 3.6 | 90        |
| 6  | Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy. <i>OncImmunology</i> , 2021, 10, 1976953.   | 4.6 | 13        |
| 7  | Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 465-e917.  | 3.7 | 13        |
| 8  | Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. <i>Cancers</i> , 2021, 13, 2807.  | 3.7 | 19        |
| 9  | Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex: A case report and literature review. <i>Molecular and Clinical Oncology</i> , 2021, 15, 186.                                     | 1.0 | 3         |
| 10 | Abstract CT111: Results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors. <i>Cancer Research</i> , 2021, 81, CT111-CT111.  | 0.9 | 2         |
| 11 | Changes in Peripheral Blood Regulatory T Cells and IL-6 and IL-10 Levels Predict Response of Pediatric Medulloblastoma and Germ Cell Tumors With Residual or Disseminated Disease to Craniospinal Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 479-490. | 0.8 | 3         |
| 12 | Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET).. <i>Journal of Clinical Oncology</i> , 2021, 39, 369-369.   | 1.6 | 7         |
| 13 | Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e494-e501.   | 3.6 | 23        |
| 14 | Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2020, 25, 33-45.  | 3.7 | 87        |
| 15 | Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients. <i>Pain</i> , 2020, 161, 127-134.  | 4.2 | 15        |
| 16 | Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 1123-1130.   | 1.1 | 9         |
| 17 | Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. , 2020, 8, e001662.   |     | 28        |
| 18 | &lt;p&gt;&lt;p&gt;Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study&lt;p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 6607-6614.  | 1.9 | 8         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and $\pm$ PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4670-4681.                                  | 7.0 | 31        |
| 20 | <p>Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9713-9719.  | 1.9 | 3         |
| 21 | Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. <i>Communications Biology</i> , 2020, 3, 226.   | 4.4 | 18        |
| 22 | DC-CIK as a widely applicable cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 601-607.   | 3.1 | 28        |
| 23 | Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup> Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382. | 6.4 | 79        |
| 24 | Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3557-3564.   | 7.0 | 4         |
| 25 | Exploring telotristat ethyl's antiproliferative effects in patients with carcinoid syndrome (TELEACE): A real-world observational study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 618-618.   | 1.6 | 2         |
| 26 | Real-world treatment patterns and survival in patients (pts) with hepatocellular carcinoma in the United States.. <i>Journal of Clinical Oncology</i> , 2020, 38, 519-519.   | 1.6 | 1         |
| 27 | Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 652-662.  | 1.4 | 106       |
| 28 | Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth. <i>Immunotherapy</i> , 2019, 11, 953-966.   | 2.0 | 8         |
| 29 | A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 1032.   | 2.6 | 9         |
| 30 | A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 909-917.  | 2.3 | 13        |
| 31 | A Phase I-II Study Using Rixin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. <i>Molecular Therapy - Oncolytics</i> , 2019, 12, 56-67.  | 4.4 | 36        |
| 32 | Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE) Tj ETQq0 0 0 rg70 Overlock 1.0 Tf 50                                    |     |           |
| 33 | Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.                                  | 1.6 | 185       |
| 34 | Functional CD3+CD8+PD1 <sup>hi</sup> T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast. <i>Clinical Breast Cancer</i> , 2019, 19, e617-e623.  | 2.4 | 8         |
| 35 | Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 505-511.                                       | 2.1 | 5         |
| 36 | Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors. <i>International Journal of Hyperthermia</i> , 2019, 36, 74-82.   | 2.5 | 21        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1453-1461.  | 3.7 | 75        |
| 38 | Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. <i>Clinical Cancer Research</i> , 2019, 25, 2725-2736.  | 7.0 | 50        |
| 39 | Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy. <i>Biochemical Journal</i> , 2019, 476, 535-546.   | 3.7 | 44        |
| 40 | Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. <i>Clinical Cancer Research</i> , 2019, 25, 1494-1504.  | 7.0 | 45        |
| 41 | A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study. <i>Clinical and Translational Oncology</i> , 2019, 21, 489-498.                   | 2.4 | 65        |
| 42 | Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. <i>Journal of Clinical Oncology</i> , 2019, 37, 635-635.          | 1.6 | 31        |
| 43 | Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 18, 5717-5724.  | 1.8 | 4         |
| 44 | Whole Recombinant <i>Saccharomyces cerevisiae</i> Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial. <i>Journal of Immunotherapy</i> , 2018, 41, 141-150.   | 2.4 | 21        |
| 45 | The role of external beam radiotherapy in the treatment of hepatocellular cancer. <i>Cancer</i> , 2018, 124, 3476-3489.  | 4.1 | 26        |
| 46 | XIAP Regulation by MNK Links MAPK and NF- $\kappa$ B Signaling to Determine an Aggressive Breast Cancer Phenotype. <i>Cancer Research</i> , 2018, 78, 1726-1738.   | 0.9 | 45        |
| 47 | CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 365-372.                      | 2.3 | 8         |
| 48 | Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 239-247.            | 3.8 | 96        |
| 49 | Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 305.  | 2.8 | 15        |
| 50 | Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with <sup>131</sup> I-MIBG. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1708-1713.  | 5.0 | 12        |
| 51 | Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. <i>Breast Cancer Research</i> , 2018, 20, 90.                    | 5.0 | 14        |
| 52 | A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3555-3555. | 1.6 | 3         |
| 53 | Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.. <i>Journal of Clinical Oncology</i> , 2018, 36, 553-553.          | 1.6 | 43        |
| 54 | Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.. <i>Journal of Clinical Oncology</i> , 2018, 36, 554-554.           | 1.6 | 39        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study.. Journal of Clinical Oncology, 2018, 36, 414-414.  | 1.6  | 10        |
| 56 | High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry.. Journal of Clinical Oncology, 2018, 36, 624-624.   | 1.6  | 1         |
| 57 | Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.. Journal of Clinical Oncology, 2018, 36, 4578-4578.  | 1.6  | 1         |
| 58 | Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. Oncolmunology, 2017, 6, e1264563.   | 4.6  | 23        |
| 59 | Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. Oncolmunology, 2017, 6, e1315495.   | 4.6  | 17        |
| 60 | Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Clinical Cancer Research, 2017, 23, 5066-5073.   | 7.0  | 62        |
| 61 | Phase I study of pazopanib plus TH-302 in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2017, 79, 611-619.  | 2.3  | 8         |
| 62 | Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. Clinical Genitourinary Cancer, 2017, 15, 31-41.e4. | 1.9  | 31        |
| 63 | <i>In Vivo</i> Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. Clinical Cancer Research, 2017, 23, 7531-7542.   | 7.0  | 15        |
| 64 | A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunology Research, 2017, 5, 942-949.  | 3.4  | 63        |
| 65 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncology, The, 2017, 18, 1182-1191.  | 10.7 | 2,058     |
| 66 | Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. , 2017, 5, 102.   |      | 31        |
| 67 | Ensituximab (E) in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results of a phase I/II clinical trial.. Journal of Clinical Oncology, 2017, 35, 3081-3081.   | 1.6  | 3         |
| 68 | Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.. Journal of Clinical Oncology, 2017, 35, 3548-3548.                   | 1.6  | 5         |
| 69 | Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. Journal of Clinical Oncology, 2017, 35, 4073-4073.  | 1.6  | 133       |
| 70 | Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE) Tj ETQqO 0 0 rgBT, Overlock 10 Tf 50   |      |           |
| 71 | Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. Journal of Clinical Oncology, 2017, 35, 519-519.  | 1.6  | 49        |
| 72 | A phase II multicenter study evaluating combination immunotherapy with pembrolizumab and peginterferon alfa-2b for advanced cholangiocarcinoma.. Journal of Clinical Oncology, 2017, 35, TPS507-TPS507.  | 1.6  | 1         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Association of improved survival (OS) and tumor control (TC) with interleukin-2 (IL2) with development of immune-related events (IREs): Data from the PROCLAIMSM registry.. Journal of Clinical Oncology, 2017, 35, 9528-9528.        | 1.6  | 0         |
| 74 | Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. European Heart Journal, 2016, 37, ehv611. | 2.2  | 25        |
| 75 | Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden. Journal of Gastrointestinal Oncology, 2016, 7, 875-881.  | 1.4  | 4         |
| 76 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, The, 2016, 17, 1590-1598.                                      | 10.7 | 594       |
| 77 | Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 1533-1544.                  | 4.2  | 89        |
| 78 | A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 577-584.  | 2.3  | 12        |
| 79 | Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas. Clinical Colorectal Cancer, 2016, 15, 345-351.        | 2.3  | 67        |
| 80 | Immunotherapy in Gastrointestinal Malignancies. , 2016, , 27-69.  |      | 0         |
| 81 | Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. Current Treatment Options in Oncology, 2016, 17, 41.   | 3.0  | 33        |
| 82 | Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncology, The, 2016, 17, 883-895.   | 10.7 | 1,091     |
| 83 | The Outlook for Immune Checkpoint Targeting Strategies in Colorectal Cancer. Current Colorectal Cancer Reports, 2016, 12, 51-56.  | 0.5  | 0         |
| 84 | Immunotherapy for Resected Pulmonary Metastases. Thoracic Surgery Clinics, 2016, 26, 69-78.   | 1.0  | 3         |
| 85 | Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2016, 34, 100-100.  | 1.6  | 10        |
| 86 | Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 3548-3548.   | 1.6  | 4         |
| 87 | Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.. Journal of Clinical Oncology, 2016, 34, 4501-4501.  | 1.6  | 36        |
| 88 | Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).. Journal of Clinical Oncology, 2016, 34, e15013-e15013.  | 1.6  | 2         |
| 89 | Sequential administration of high-dose interleukin-2 and ipilimumab in patients with metastatic melanoma.. Journal of Clinical Oncology, 2016, 34, e21041-e21041.   | 1.6  | 4         |
| 90 | Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, TPS3103-TPS3103.                              | 1.6  | 5         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).. Journal of Clinical Oncology, 2016, 34, 511-511.   | 1.6 | 1         |
| 92  | X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 687-687.   | 1.6 | 1         |
| 93  | A phase II therapeutic, open label, multi-center clinical trial of NPC-1C, a chimeric monoclonal antibody(mAb), in adults with chemotherapy refractory metastatic colorectal cancer (mCRC), initial results.. Journal of Clinical Oncology, 2016, 34, 500-500.   | 1.6 | 3         |
| 94  | Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen (CEA), in patients with advanced gastrointestinal (GI) adenocarcinomas.. Journal of Clinical Oncology, 2016, 34, 320-320.   | 1.6 | 2         |
| 95  | Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2.. Journal of Clinical Oncology, 2016, 34, e21039-e21039.  | 1.6 | 0         |
| 96  | Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry.. Journal of Clinical Oncology, 2016, 34, 4548-4548.   | 1.6 | 0         |
| 97  | A phase 2 study of NEO-102 (ensituximab), a novel chimeric monoclonal antibody, in adult patients (pts) with unresectable, metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 3080-3080.  | 1.6 | 0         |
| 98  | Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Design, Development and Therapy, 2015, 9, 5075.   | 4.3 | 160       |
| 99  | Checkpoint blockade in combination with cancer vaccines. Vaccine, 2015, 33, 7377-7385.   | 3.8 | 33        |
| 100 | Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncolmunology, 2015, 4, e1026529.  | 4.6 | 79        |
| 101 | Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunology, Immunotherapy, 2015, 64, 977-987.   | 4.2 | 44        |
| 102 | Safety, immunogenicity, and clinical activity of the immunotherapeutic vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian tube, or peritoneal cancer.. Journal of Clinical Oncology, 2015, 33, 3072-3072.   | 1.6 | 2         |
| 103 | Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal T cell and antibody responses against HER2.. Journal of Clinical Oncology, 2015, 33, 3081-3081.   | 1.6 | 4         |
| 104 | Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.. Journal of Clinical Oncology, 2015, 33, 7503-7503.  | 1.6 | 38        |
| 105 | A phase II multicenter study of the chimeric monoclonal antibody NEO102 (N) in adults with refractory colorectal cancer (CC).. Journal of Clinical Oncology, 2015, 33, e14013-e14013.  | 1.6 | 1         |
| 106 | A phase I/II multicenter study of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic (PC) and colorectal cancer (CC).. Journal of Clinical Oncology, 2015, 33, 240-240.   | 1.6 | 1         |
| 107 | Tumor profiling of biliary tract carcinomas to reveal distinct molecular alterations and potential therapeutic targets.. Journal of Clinical Oncology, 2015, 33, 285-285.  | 1.6 | 14        |
| 108 | A phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).. Journal of Clinical Oncology, 2015, 33, TPS489-TPS489. | 1.6 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfirinox (F).. Journal of Clinical Oncology, 2015, 33, TPS499-TPS499.                              | 1.6 | 1         |
| 110 | High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).. Journal of Clinical Oncology, 2015, 33, 423-423.   | 1.6 | 3         |
| 111 | The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion. Oncotarget, 2015, 6, 41350-41359.   | 1.8 | 14        |
| 112 | Overall survival of metastatic melanoma (mM) treated with high dose IL-2 (HD IL-2) followed by anti-CTLA4 (IPI) and/or anti-PD-1/PDL1 (aPD1) therapy: Analysis of the prospective cohort of the PROCLAIM national registry.. Journal of Clinical Oncology, 2015, 33, e20071-e20071.   | 1.6 | 0         |
| 113 | Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIMHD IL-2 National Registry.. Journal of Clinical Oncology, 2015, 33, e15609-e15609.   | 1.6 | 0         |
| 114 | Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. , 2014, 2, 20.   |     | 4         |
| 115 | Designing effective vaccines for colorectal cancer. Immunotherapy, 2014, 6, 913-926.  | 2.0 | 3         |
| 116 | Immunotherapeutic treatment of metastatic colorectal cancer using ETBX-011.. Journal of Clinical Oncology, 2014, 32, 3093-3093.   | 1.6 | 3         |
| 117 | High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).. Journal of Clinical Oncology, 2014, 32, 4523-4523.   | 1.6 | 4         |
| 118 | Phase I/II clinical and immunologic assessment of immunotherapeutic vaccine, DPX-Survivac in women with ovarian, Fallopian tube, or peritoneal cancer (OC).. Journal of Clinical Oncology, 2014, 32, 5555-5555.   | 1.6 | 1         |
| 119 | Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry.. Journal of Clinical Oncology, 2014, 32, 9054-9054.   | 1.6 | 3         |
| 120 | Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS3114-TPS3114.  | 1.6 | 10        |
| 121 | A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.. Journal of Clinical Oncology, 2014, 32, 177-177.  | 1.6 | 20        |
| 122 | High-dose interleukin-2 registry, PROCLAIM: Modern data on toxicities and outcomes.. Journal of Clinical Oncology, 2014, 32, 430-430.   | 1.6 | 2         |
| 123 | A phase Ib/IIa study of NEO-102: A therapeutic antibody to treat pancreatic and colorectal cancers.. Journal of Clinical Oncology, 2014, 32, 243-243.   | 1.6 | 1         |
| 124 | A phase Ib/IIa study of NEO-102: A therapeutic antibody for the treatment of advanced pancreatic and colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 3072-3072.   | 1.6 | 0         |
| 125 | A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).. Journal of Clinical Oncology, 2014, 32, TPS4159-TPS4159. | 1.6 | 0         |
| 126 | Molecular profiling of bile duct and gallbladder cancer to identify different therapeutic options.. Journal of Clinical Oncology, 2014, 32, 4097-4097.  | 1.6 | 0         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Functional genomic screens and identification of signaling pathways in oxaliplatin-resistance in colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 3611-3611.   | 1.6 | 0         |
| 128 | Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 391-397.   | 0.5 | 9         |
| 129 | Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunology, Immunotherapy, 2013, 62, 1293-1301.  | 4.2 | 76        |
| 130 | A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer. Annals of Surgery, 2013, 258, 879-886.   | 4.2 | 111       |
| 131 | Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study.. Journal of Clinical Oncology, 2013, 31, 3030-3030.   | 1.6 | 4         |
| 132 | A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs.. Journal of Clinical Oncology, 2013, 31, 4031-4031.         | 1.6 | 10        |
| 133 | Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, 4040-4040.  | 1.6 | 8         |
| 134 | Immunologic Targeting of FOXP3 in Inflammatory Breast Cancer Cells. PLoS ONE, 2013, 8, e53150.  | 2.5 | 16        |
| 135 | A molecular profile of colorectal cancer to guide prognosis and therapy after resection of primary or metastatic disease.. Journal of Clinical Oncology, 2013, 31, 339-339.   | 1.6 | 1         |
| 136 | A phase II study of NPC-1C: A novel therapeutic monoclonal antibody (mab) to treat pancreatic (P) and colorectal (CR) cancers.. Journal of Clinical Oncology, 2013, 31, 3070-3070.  | 1.6 | 1         |
| 137 | Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e287-e293.  | 3.8 | 4         |
| 138 | Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. Cancer Immunology, Immunotherapy, 2012, 61, 1941-1951.  | 4.2 | 22        |
| 139 | Improved Time to Progression for Transarterial Chemoembolization Compared With Transarterial Embolization for Patients With Unresectable Hepatocellular Carcinoma. Clinical Colorectal Cancer, 2012, 11, 185-190.   | 2.3 | 15        |
| 140 | Novel Recombinant Alphaviral and Adenoviral Vectors for Cancer Immunotherapy. Seminars in Oncology, 2012, 39, 305-310.  | 2.2 | 14        |
| 141 | Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition. Journal of Translational Medicine, 2012, 10, 28.   | 4.4 | 77        |
| 142 | Effect of the loss of the type III TGF $\beta$ 2 receptor during tumor progression on tumor microenvironment: Preclinical development of TGF $\beta$ 2 inhibition and TGF $\beta$ 2-related biomarkers to enhance immunotherapy efficacy.. Journal of Clinical Oncology, 2012, 30, 10563-10563. | 1.6 | 3         |
| 143 | Effect of the vaccine Ad5 [E1-, E2b-]-CEA(6D) on CEA-directed CMI responses in patients with advanced CEA-expressing malignancies in a phase I/II clinical trial.. Journal of Clinical Oncology, 2012, 30, 2585-2585.   | 1.6 | 38        |
| 144 | A phase I/IIA safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.. Journal of Clinical Oncology, 2012, 30, 233-233.   | 1.6 | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Discovering pathways in the tumor microenvironment important for recurrence-free survival in patients with colorectal liver metastasis.. Journal of Clinical Oncology, 2012, 30, 480-480.                                | 1.6 | 9         |
| 146 | Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 490-490.  | 1.6 | 1         |
| 147 | Predictive and prognostic markers of recurrence after resection of primary or metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 447-447.  | 1.6 | 0         |
| 148 | Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients.. Journal of Clinical Oncology, 2012, 30, 2588-2588.            | 1.6 | 0         |
| 149 | A phase I safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.. Journal of Clinical Oncology, 2012, 30, 2517-2517.  | 1.6 | 3         |
| 150 | Ad5 immunity after multiple safe, homologous immunizations against tumor-associated antigens with new recombinant Ad5 vector.. Journal of Clinical Oncology, 2012, 30, 85-85.  | 1.6 | 0         |
| 151 | Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunologic Research, 2011, 49, 235-247.  | 2.9 | 11        |
| 152 | MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. Journal of Proteomics, 2011, 74, 728-743.                           | 2.4 | 18        |
| 153 | CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Review of Vaccines, 2011, 10, 733-742.   | 4.4 | 36        |
| 154 | Phase I Study Utilizing a Novel Antigen-Presenting Cell-Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients. Clinical Cancer Research, 2011, 17, 4844-4853.      | 7.0 | 129       |
| 155 | MHC Class I-Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer. Clinical Cancer Research, 2011, 17, 3408-3419.         | 7.0 | 35        |
| 156 | Depletion of Human Regulatory T Cells. Methods in Molecular Biology, 2011, 707, 219-231.   | 0.9 | 16        |
| 157 | Synergism from combined immunologic and pharmacologic inhibition of HER2 <i>in vivo</i> . International Journal of Cancer, 2010, 126, 2893-2903.   | 5.1 | 17        |
| 158 | An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. Journal of Clinical Investigation, 2010, 120, 3234-3241. | 8.2 | 98        |
| 159 | A year of successful cancer vaccines points to a path forward. Current Opinion in Molecular Therapeutics, 2010, 12, 11-3.  | 2.8 | 21        |
| 160 | Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. Expert Opinion on Biological Therapy, 2009, 9, 331-339.   | 3.1 | 43        |
| 161 | Advances in immunotherapy for colorectal malignancies. Current Colorectal Cancer Reports, 2008, 4, 177-183.  | 0.5 | 0         |
| 162 | Comment regarding benefit in phase 1 oncology trials. Clinical Trials, 2008, 5, 626-626.   | 1.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. <i>Blood</i> , 2008, 112, 610-618.  | 1.4 | 282       |
| 164 | Editorial Board Focus " February 2007. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 157-160.  | 3.1 | 0         |
| 165 | Current Immunotherapeutic Strategies in Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2007, 16, 873-900.  | 1.5 | 11        |
| 166 | Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. <i>Journal of Translational Medicine</i> , 2007, 5, 42. | 4.4 | 42        |
| 167 | Supportive Care in the Management of Colon Cancer. <i>Supportive Cancer Therapy</i> , 2006, 3, 158-170.   | 0.3 | 5         |
| 168 | Enumerating Antigen-Specific T-Cell Responses in Peripheral Blood. <i>Journal of Immunotherapy</i> , 2005, 28, 63-72.   | 2.4 | 70        |
| 169 | Adjuvant Therapy of Colon Cancer: Current Status and Future Developments. <i>Clinics in Colon and Rectal Surgery</i> , 2005, 18, 224-231.   | 1.1 | 5         |
| 170 | Virus-based therapies for colon cancer. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 1627-1633.   | 3.1 | 9         |
| 171 | Phase I Study of Immunization with Dendritic Cells Modified with Fowlpox Encoding Carcinoembryonic Antigen and Costimulatory Molecules. <i>Clinical Cancer Research</i> , 2005, 11, 3017-3024.            | 7.0 | 127       |
| 172 | Recent developments in therapeutic cancer vaccines. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 108-113.  | 4.3 | 48        |
| 173 | Combining cancer vaccines with chemotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2813-2820.   | 1.8 | 13        |
| 174 | A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. <i>Journal of Translational Medicine</i> , 2005, 3, 9.  | 4.4 | 870       |
| 175 | Technology evaluation: Regin-G, Epeius Biotechnologies. <i>Current Opinion in Molecular Therapeutics</i> , 2005, 7, 164-9.  | 2.8 | 8         |
| 176 | Perspectives in colorectal cancer - Sixth Annual Conference. <i>Metastatic colorectal cancer. IDrugs: the Investigational Drugs Journal</i> , 2005, 8, 974-7.   | 0.7 | 0         |
| 177 | Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. <i>Current Opinion in Molecular Therapeutics</i> , 2005, 7, 588-97.  | 2.8 | 32        |
| 178 | How does the immune system attack cancer?. <i>Current Problems in Surgery</i> , 2004, 41, 15-132.   | 1.1 | 14        |
| 179 | Immunotherapy of surgical malignancies. <i>Current Problems in Surgery</i> , 2004, 41, 15-132.  | 1.1 | 5         |
| 180 | Preparation of Peptide-Loaded Dendritic Cells for Cancer Immunotherapy. <i>Molecular Biotechnology</i> , 2003, 25, 95-100.  | 2.4 | 4         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Title is missing!. Journal of Neuro-Oncology, 2003, 64, 161-176.   | 2.9 | 6         |
| 182 | The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. Journal of Neuro-Oncology, 2003, 64, 161-176.   | 2.9 | 33        |
| 183 | HER2 Dendritic Cell Vaccines. Clinical Breast Cancer, 2003, 3, S164-S172.  | 2.4 | 26        |
| 184 | Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA. Cancer Investigation, 2003, 21, 341-349.  | 1.3 | 159       |
| 185 | Recent areas of development for dendritic cell vaccines. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 339-350.   | 0.5 | 0         |
| 186 | Dendritic Cell Recovery Following Nonmyeloablative Allogeneic Stem Cell Transplants. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 659-668.   | 1.8 | 16        |
| 187 | Immunoregulatory T cells in cancer immunotherapy. Expert Opinion on Biological Therapy, 2002, 2, 827-834.  | 3.1 | 48        |
| 188 | Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells. Annals of Surgery, 2002, 235, 540-549.   | 4.2 | 177       |
| 189 | Dendritic Cell-Based Vaccines in Cancer. American Journal of Cancer, 2002, 1, 313-322.   | 0.4 | 0         |
| 190 | Dendritic cell maturation in active immunotherapy strategies. Expert Opinion on Biological Therapy, 2002, 2, 35-43.  | 3.1 | 33        |
| 191 | 38th Annual Meeting of the American Society of Clinical Oncology. Expert Opinion on Emerging Drugs, 2002, 7, 335-338.  | 2.4 | 0         |
| 192 | Current status of adoptive immunotherapy of malignancies. Expert Opinion on Biological Therapy, 2002, 2, 237-247.  | 3.1 | 19        |
| 193 | DNA and RNA Modified Dendritic Cell Vaccines. World Journal of Surgery, 2002, 26, 819-825.   | 1.6 | 14        |
| 194 | The Feasibility and Safety of Immunotherapy with Dendritic Cells Loaded with CEA mRNA Following Neoadjuvant Chemoradiotherapy and Resection of Pancreatic Cancer. International Journal of Gastrointestinal Cancer, 2002, 32, 1-6. | 0.4 | 82        |
| 195 | RNA-Transfected Dendritic Cells as Immunogens. , 2002, , 199-203.  |     | 0         |
| 196 | CEA loaded dendritic cell vaccines. Cancer Chemotherapy and Biological Response Modifiers, 2002, 20, 385-90.   | 0.5 | 4         |
| 197 | Surrogate Markers of Effective Anti-Tumor Immunity. Annals of Surgical Oncology, 2001, 8, 190-191.   | 1.5 | 4         |
| 198 | Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas. Annals of Surgical Oncology, 2001, 8, 758-765.  | 1.5 | 203       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 199 | Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Does Not Influence Survival. <i>Annals of Surgical Oncology</i> , 2001, 8, 801-806.   | 1.5  | 122       |
| 200 | Surrogate markers of response to cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2001, 1, 153-158.  | 3.1  | 7         |
| 201 | A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon- $\gamma$ treatment. <i>Blood</i> , 2000, 96, 3499-3504.  | 1.4  | 131       |
| 202 | Preoperative Mobilization of Circulating Dendritic Cells by Flt3 Ligand Administration to Patients With Metastatic Colon Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 3883-3893.   | 1.6  | 120       |
| 203 | Optimizing Dendritic Cell Function by Genetic Modification. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1198-1199.  | 6.3  | 2         |
| 204 | Educational Review Cellular and Biological Therapies of Gastrointestinal Tumors: Overview of Clinical Trials. <i>Annals of Surgical Oncology</i> , 1999, 6, 218-223.  | 1.5  | 3         |
| 205 | Induction of carcinoembryonic antigen (cea)-specific cytotoxic t-lymphocyte responses in vitro using autologous dendritic cells loaded with cea peptide or cea rna in patients with metastatic malignancies expressing cea. <i>International Journal of Cancer</i> , 1999, 82, 121-124. | 5.1  | 151       |
| 206 | The Role of IL-13 in the Generation of Dendritic Cells in Vitro. <i>Journal of Immunotherapy</i> , 1999, 22, 506-513.   | 2.4  | 38        |
| 207 | A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. <i>Clinical Cancer Research</i> , 1999, 5, 1331-8.                | 7.0  | 220       |
| 208 | Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. <i>Nature Biotechnology</i> , 1998, 16, 364-369.  | 17.5 | 383       |
| 209 | Dendritic cell-based approaches to cancer immunotherapy. <i>Expert Opinion on Investigational Drugs</i> , 1998, 7, 1617-1627.   | 4.1  | 4         |
| 210 | Induction of Primary, Human Antigen-Specific Cytotoxic T Lymphocytes In Vitro Using Dendritic Cells Pulsed with Peptides. <i>Journal of Immunotherapy</i> , 1998, 21, 32-40.  | 2.4  | 42        |
| 211 | Generation of Dendritic Cells In Vitro From Peripheral Blood Mononuclear Cells With Granulocyte-Macrophage-Colony-Stimulating Factor, Interleukin-4, and Tumor Necrosis Factor- $\alpha$ for Use in Cancer Immunotherapy. <i>Annals of Surgery</i> , 1997, 226, 6-16.                   | 4.2  | 90        |